Reengineering Cervical Cancer Screening for the 21st Century: Joint Action for a Novel Up-to-date and Sustainable Screening Program
Launched by INSTITUTO DE SAUDE PUBLICA DA UNIVERSIDADE DO PORTO · Mar 31, 2025
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Vaccination against human papillomavirus (HPV) is highly effective and is expected to reduce substantially the burden of cervical cancer (CC), but cervical cancer screening (CCS) remains necessary for females who were not covered by the vaccination plans, those who remain non-adherent to vaccination, and for early detection of the cervical lesions not prevented by the vaccine. However, the sustainability of CCS programs will be challenged by the expectedly dramatic reduction in frequency of cervical precancerous lesions. A paradigm shift for CCS programs, towards a substantial improvement o...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Females fulfilling the eligibility criteria for CCS, as defined by the current guidelines for the organized screening program in Portugal.
- Exclusion Criteria:
- • Not having a Portuguese mobile phone number or a Portuguese address available in the clinical/administrative records of the primary healthcare units;
- • Any of the exclusion criteria for CCS, as defined by the current guidelines for the organized screening program in Portugal.
About Instituto De Saude Publica Da Universidade Do Porto
The Instituto de Saúde Pública da Universidade do Porto (ISPUP) is a leading research institution dedicated to advancing public health through rigorous scientific inquiry and community engagement. As a prominent sponsor of clinical trials, ISPUP is committed to generating evidence-based solutions to pressing health challenges, fostering collaborations among researchers, healthcare professionals, and stakeholders. With a focus on epidemiology, health promotion, and disease prevention, ISPUP aims to enhance population health outcomes and inform public health policies, leveraging cutting-edge methodologies and interdisciplinary approaches in its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vila Nova De Gaia, , Portugal
Patients applied
Trial Officials
Nuno Lunet, PhD
Principal Investigator
Universidade do Porto
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported